Hong Kong Personal Products Stock News

Comba Telecom Systems Holdings (SEHK:2342) is making headlines after the board announced a key change in its independent director lineup. Ms. Wong Lok Lam is stepping down. Dr. Tan Khee Giap will step in, bringing extensive cross-sector expertise. See our latest analysis for Comba Telecom Systems Holdings. After a remarkable surge earlier this year, Comba Telecom’s share price has recently cooled. The stock posted a 1-day gain of 2.46% but experienced a 30-day drop of 9.91%. Still, the...

Chinese automakers are making real headway in South Africa, recently surpassing some long-established Western and Japanese rivals thanks to attractive pricing and loaded features. Great Wall Motor (SEHK:2333) stands out as local government incentives now encourage even more investment, with a focus on hybrid and electric vehicles. See our latest analysis for Great Wall Motor. Great Wall Motor’s push into South Africa is grabbing headlines, but it comes amid momentum that has been building for...

361 Degrees International (SEHK:1361) just posted its third quarter sales update, showing about 10% year-on-year retail sales growth for both core and kids brands. E-commerce sales climbed about 20% compared to last year. See our latest analysis for 361 Degrees International. The strong third quarter sales update follows a solid year for 361 Degrees International, with the stock climbing 41% year-to-date and delivering a remarkable 57% total shareholder return over the past 12 months...

The Industrial and Commercial Bank of China (SEHK:1398) just made headlines as its Luxembourg branch completed the first Swap Connect transaction in Europe. This development opens fresh connections between international investors and China’s onshore derivatives markets. See our latest analysis for Industrial and Commercial Bank of China. ICBC’s shift toward connecting global investors with Chinese markets has grabbed attention, but it is not the only story this year. After...

China Resources Power Holdings Company Limited's ( HKG:836 ) price-to-earnings (or "P/E") ratio of 7.2x might make it...

Most readers would already know that Guangdong Investment's (HKG:270) stock increased by 3.0% over the past week...

Earlier this week, Huobi founder Li Lin, alongside leading Asian crypto investors including backers with ties to Meitu, announced the raising of US$1 billion to establish an Ethereum-focused digital asset trust structured through a Nasdaq-listed shell company. The initiative's scale and participation from well-known digital asset firms have brought renewed attention to Meitu, given its prior crypto engagement and the sector’s growing momentum in institutional Ethereum exposure. We'll explore...

Joy City Property (SEHK:207) has entered into a new USD 150 million term loan facility with a consortium of lenders. The company aims to refinance existing debt and strengthen its capital structure. The deal closely links future loan terms to the ongoing control of COFCO Corporation. See our latest analysis for Joy City Property. Joy City Property’s latest loan agreement comes after a remarkable run for the shares. After a muted start to the year, momentum has surged, reflected in a 54% share...

Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns within reach of every...

Amidst the backdrop of global market volatility and evolving economic conditions, Asian small-cap stocks are garnering attention, particularly as investors navigate the complexities of U.S.-China trade tensions and fluctuating interest rates. In this environment, identifying stocks that demonstrate strong fundamentals and insider buying can be key indicators of potential value, offering intriguing opportunities for those looking to explore the Asian small-cap landscape.

As global markets navigate a period of economic uncertainty, with trade tensions and monetary policy shifts making headlines, investors are increasingly seeking opportunities in diverse sectors. Penny stocks, often associated with smaller or newer companies, present intriguing possibilities for those looking to explore beyond the mainstream market. Despite being considered an outdated term by some, these stocks continue to offer potential growth at accessible price points when backed by solid...

Chinese biotech company Hansoh Pharmaceutical Group has entered a licensing agreement worth up to US$1.45 billion with Roche, granting Roche exclusive global rights to develop, manufacture, and commercialise an investigational treatment for colorectal cancer and other solid tumours. This collaboration gives Hansoh access to a major global pharmaceutical partner and spotlights the company's advancing drug pipeline in oncology. We’ll examine what this expansive partnership with Roche could...

On October 17, 2025, Precision Tsugami (China) announced that it expects to report a profit attributable to owners of approximately RMB 502 million for the half-year ended September 30, 2025, representing a substantial increase compared to the prior-year period. The anticipated improvement reflects rising demand in sectors such as new energy vehicles and artificial intelligence, as well as operational efficiencies boosting profitability. We'll explore how strengthening demand from emerging...

As global markets navigate a landscape marked by U.S.-China trade tensions and monetary policy shifts, investors are increasingly looking toward Asia for opportunities in dividend stocks. In such a dynamic environment, a good dividend stock is typically characterized by its ability to maintain stable payouts and demonstrate resilience amid economic fluctuations.

Key Insights AInnovation Technology Group's significant retail investors ownership suggests that the key decisions are...

Chia Tai Enterprises International's (HKG:3839) stock is up by a considerable 50% over the past three months. Given...

We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

As global markets navigate a period of volatility marked by trade tensions and monetary policy shifts, investors are increasingly turning their attention to Asia for opportunities. In this context, dividend stocks can offer a compelling option for those seeking income stability amid economic uncertainties.

As the Asian tech sector navigates a landscape marked by evolving U.S.-China trade dynamics and ongoing economic adjustments, investors are keenly observing how these factors impact growth trajectories. In such an environment, identifying high-growth tech stocks involves assessing companies that demonstrate resilience through innovation and adaptability in response to shifting market conditions.

As global markets navigate a landscape of economic uncertainties, including U.S.-China trade tensions and monetary policy shifts, Asian equities present intriguing opportunities for value investors. In this environment, identifying undervalued stocks becomes crucial as investors seek companies with strong fundamentals that are trading below their intrinsic value estimates.

If you have been watching Sino Biopharmaceutical, you are probably wondering what to make of this stock after such a rollercoaster ride. The past year has brought a surge that few predicted, with the stock up an eye-catching 135.6% since the start of the year and 95.3% over the last twelve months. Even looking back three years, the company has notched an impressive 83.5% gain. Yet, this momentum hit a speed bump recently, with prices dropping 6.7% in the last week and falling 13.2% over the...

Meitu (SEHK:1357) shares have seen a dip, with the stock slipping over 5% in recent trading. Investors are watching closely as the company navigates shifting market sentiment and re-evaluates its business strategies. See our latest analysis for Meitu. Meitu's recent slide comes after a year marked by dramatic momentum shifts, with the share price posting an impressive year-to-date return of 185.76%. Short-term volatility aside, long-term investors have enjoyed a stellar one-year total...

Simcere Pharmaceutical Group (SEHK:2096) has advanced its oncology program with the first U.S. patient dosed in the Phase 1 trial of SIM0505 for advanced solid tumors. This development expands the clinical reach beyond China and draws investor attention to ongoing trial progress. See our latest analysis for Simcere Pharmaceutical Group. Simcere’s recent momentum is hard to miss, with the stock’s 91.5% year-to-date share price return fueled by progress in its expanding oncology pipeline...